BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Kite Pharma, Inc. Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors


3/9/2011 6:29:21 AM

LOS ANGELES--(BUSINESS WIRE)-- Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, today announced that it has raised $15 million in an initial round of financing through a private placement with a syndicate of venture and qualified investors. Riverbank Capital Securities Inc., a FINRA member broker dealer, acted as placement agent in connection with the financing.

“We are very pleased with the high level of interest in Kite’s strategy and activities, which allowed us to rapidly close this oversubscribed round of financing,” said Aya Jakobovits, Ph.D., President and Chief Executive Officer of Kite. “The funds will allow us to grow the company, advance our products into clinical development and to expand our pre-clinical pipeline.”

In connection with the financing, Mr. David Bonderman, a founding partner of TPG Capital and a lead investor of the round, has joined Kite’s Board of Directors.

“We are excited to welcome Mr. Bonderman to Kite’s Board of Directors. We will greatly benefit from his vast business experience,” said Arie Belldegrun, M.D., FACS, Executive Chairman and Founder of Kite. “Immunotherapy is the next frontier for potential breakthroughs in cancer therapies. Having assembled an outstanding team at Kite, we aim to capitalize on the latest developments and become a leader in the field.”

About Kite Pharma

Active immunotherapy is an emerging therapeutic modality for the treatment of multiple cancer indications. Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the design and development of cutting-edge immunotherapeutic products to treat different cancer indications. Kite's lead products include antigens associated with a wide variety of tumor types, and are initially being developed for the treatment of renal cell carcinoma and hepatocellular carcinoma. These potential therapies are designed to stimulate a patient's own immune system to help fight cancer and could represent novel strategies for the management and treatment of these otherwise incurable diseases. Kite is based in Los Angeles, CA. For more information, visit the company’s website at www.kitepharma.com.

Contact:

Kite Pharma, Inc. Aya Jakobovits, Ph.D., 310-824-9999 President and Chief Executive Officer ajakobovits@kitepharma.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES